ArticleCancer cell international2026
The anti-leukemic effects of vitamin K4 by modulating the JAK/STAT signaling pathway.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundVitamin K4 (VK4) is a hemostasis medicine used in clinical practice. It has also been reported to possess anti-cancer properties in types of solid tumors, however, its antitumor effects in leukemia cells are unknown. We aimed to investigate the anti-leukemia role of VK4 and the involved mechanisms.
methodsCCK-8 was used to detect the cytotoxic activity, and flow cytometry was applied to test cell cycle, apoptosis and mitochondrial membrane potential (MMP) level in human leukemia cells. Western bolting was conducted to examine the protein expression level. A xenografting leukemia model was established to explore the anti-leukemia effects triggered by VK4 in vivo.
resultsVK4 inhibited the proliferation of human leukemia cell lines by inducing the cell cycle arrest and mitochondrial-mediated apoptosis in HL60, Jurkat and K562 cells. MMP level was also observed to be reduced under the treatment of VK4 in these three leukemia cell lines. Further studies found that VK4 inhibited the activation of JAK-STAT signaling pathway by decreasing phosphorated JAK2 and STAT3/5. The pretreatment of AG490, an inhibitor for JAK2/3 and STAT3 could significantly reverse the effect of VK4 on cell proliferation in HL60 and K562 cells. Moreover, data from HL60-xenograft model in BALB/c nude mice demonstrated that VK4 could inhibit the proliferation of HL60 in vivo in a dose-dependent manner.
conclusionVK4 exhibited a significant anti-leukemia activity by inducing cell cycle arrest and apoptosis in human leukemia cell lines through inhibiting the JAK/STAT signaling pathway. The anti-leukemia effects both in vitro and in vivo indicated that VK4 might be developed as a promising therapeutic candidate against leukemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.